Cancer Letters
Volume 224, Issue 2 , Pages 203-212 , 28 June 2005

Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer

  • Lev M. Berstein

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +7 812 596 8654; fax: +7 812 596 8947.

Received 4 August 2004 ,Revised 25 October 2004 ,Accepted 4 November 2004.

References 

  1. Lugaro G, Giannattasio G, Torti G, Perani G. Studies on the antitumoral activity of the biguanides. V. Effect on the respiration of tumor cells. Arch. Ital. Patol. Clin. Tumori. 1967;10:211–222
  2. Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology. 1968;22:185–207
  3. Berstein LM, Pozharisski KM, Dilman VM. Effects of misclerone (clofibrate) on dimethylhydrazine-induced intestinal carcinogenesis in rats. Oncology. 1982;39:331–335
  4. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest. 1985;76:1748–1754
  5. Schmidt C. Metabolomics takes its place as latest up-and-coming ‘omic’ science. J. Natl. Cancer Inst. 2004;96:732–734
  6. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?. J. Intern. Med. 2000;247:301–310
  7. Dilman VM. Four Models of Medicine. Leningrad: Meditsina; 1987;p. 199
  8. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 2003;24:278–301
  9. Dilman VM. Development, Ageing and Disease. A New Rationale for an Intervention Strategy. Switzerland: Harwood Academic Publishers; 1994;p. 387
  10. Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, et al. Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology. 1982;39:13–19
  11. Roffo A, Thomas J. La Chemie du Cancer, Paris. 1933;p. 336
  12. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspectives. Annu. Rev. Nutr. 1992;12:391–416
  13. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. J. Am. Med. Assoc. 1996;275:55–60
  14. Guize L, Benetos A, Thomas F, Malmejac A, Ducimetre P. Cholesterolemia and total, cardiovascular and cancer mortality. Study of a cohort of 220,000 people. Bull. Acad. Natl. Med. 1998;182:631–647
  15. Lieberman DA, Prindiville S, Weiss DG, Willett W, VA Cooperative Study Group 380 . Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. J. Am. Med. Assoc. 2003;290:2959–2967
  16. Dalen JE, Dalton WS. Does lowering of cholesterol cause cancer?. J. Am. Med. Assoc. 1996;275:67–69
  17. Shinitzky M. Membrane fluidity in malignancy. Adversative and recuperative. Biochim. Biophys. Acta. 1984;738:251–262
  18. Singh RP, Kumar R, Kapur N. Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 2003;22:75–92
  19. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J. Cell Biochem. 2004;91:54–69
  20. Reaven G. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995;75:473–486
  21. Dilman VM. The Law of Deviation of Homeostasis and Diseases of Aging. Boston: J. Wright PSG Inc; 1981;p. 380
  22. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am. J. Epidemiol. 2003;157:1092–1100
  23. Cheraskin E, Ringersdorf WM, Aspray DW. Cancer proneness profile. A study of ponderal index and blood glucose. Geriatrics. 1969;24:121–125
  24. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140–1142
  25. Poretzky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocrinol. Rev. 1999;20:535–582
  26. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer. 2004;4:505–518
  27. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in insulin resistance and obesity-related diseases. Horm. Res. 2003;60:56–59
  28. Catalano S, Marsico S, Giordano C, Mauro L, Ando S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 2003;278:28668–28676
  29. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 2004;89:1102–1107
  30. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 2001;86:3574–3578
  31. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J. Natl. Cancer Inst. 2004;96:546–553
  32. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 2002;20:42–51
  33. Berstein LM. Macrosomy, Obesity and Cancer. New York: Nova Sci. Publ.; 1997;p. 195
  34. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J. Clin. Oncol. 2002;20:1128–1143
  35. McTiernan A. Obesity and cancer: potential management strategies. American Society of Clinical Oncology (ASCO) Educational Book, 40th Annual Meeting. 2004;pp. 567–571
  36. Goodwin PJ. Obesity and cancer outcomes. American Society of Clinical Oncology (ASCO) Educational Book, 40th Annual Meeting. 2004;pp. 562–566
  37. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int. J. Oncol. 2003;23:1055–1069
  38. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin. Cancer Res. 2003;9:10–19
  39. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, et al. Molecular mechanisms of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003;15:327–338
  40. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabetes Med. 2003;20:743–745
  41. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879–1894
  42. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29:S28–S35
  43. Caraci F, Chisari M, Frasca G, Chiechio S, Salomone S, Pinto A, et al. Effects of phenformin on the proliferation of human tumor cell lines. Life Sci. 2003;74:643–650
  44. Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, Bobrov JF, Pliss GB. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary glands of rats. Archiv f. Geschwulstf. 1978;43:1–8
  45. Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology. 2003;4:303–313
  46. Bonnefont-Rousselot D, Raji B, Walrand S, Gardes-Albert M, Jore D, Legrand A, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism. 2003;52:586–589
  47. Spiegelman BM. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507–514
  48. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52:667–674
  49. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, et al. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003;33:655–780
  50. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferators-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst. 2000;92:418–423
  51. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419–429
  52. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 2000;60:1604–1608
  53. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. J. Clin. Invest. 2000;30:871–878
  54. Fenton SL, Luong QT, Sarafeim A, Mustard KJ, Pound J, Desmond JC, et al. Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease. Leukemia. 2003;17:568–575
  55. Karpe F, Frayn KN. The nicotinic acid receptor—a new mechanism for an old drug. Lancet. 2004;363:1892–1894
  56. Kirkland JB. Niacin and carcinogenesis. Nutr. Cancer. 2003;46:110–118
  57. Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial cancer in patients with diabetes mellitus. Int. J. Cancer. 1997;71:360–363
  58. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  59. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403
  60. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr. Diabetes Rep. 2004;4:69–75
  61. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol. Endocrinol. 2003;17:405–407
  62. Dilman VM, Berstein LM, Evtushenko TP, Tsyrlina EV, Ostroumova MN, Bobrov Ju F, et al. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch. f. Geschwulstf. 1988;58:175–183
  63. L.M. Berstein, T.P. Evtushenko, E.V. Tsyrlina, Yu.F. Bobrov, M.N. Ostroumova, I.G. Kovalenko, V.F. Semiglazov, N.N. Simonov, V.M. Dilman, Comparative study of 5- and 10-years of metabolic rehabilitation of oncological patients, In: Neuroendocrine System, Metabolism, Immunity and Cancer, St. Petersburg, 1992, pp. 102–112.
  64. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S Study). Lancet. 1994;344:1383–1389
  65. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 1998;279:1615–1622
  66. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  67. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002;105:2341–2346
  68. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J. Womens Health. 2003;12:749–756
  69. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and risk of breast cancer. J. Clin. Epidemiol. 2003;56:280–285
  70. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308–2316
  71. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J. Clin. Oncol. 2004;22:2388–2394
  72. Poynter JN, Rennert G, Bonner JD, Rennert HS, Greenson JK, Gruber SB. HMG CoA reductase inhibitors and the risk of colorectal cancer. Proceedings of the 40th ASCO Meeting, New Orleans. 2004;p. 1
  73. Shannon J, Garzotto M, Palma AJ. Statin use and prostate risk. Proceedings of the 40th ASCO Meeting, New Orleans. 2004;p. 404
  74. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR)γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 2003;79:391–397
  75. Debrock G, Vanhentenrijk V, Scot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer. 2003;89:1409–1412
  76. Dellavalle RP, Nicholas MK, Schilling LM. Melanoma chemoprevention: a role for statins or fibrates?. Am. J. Ther. 2003;10:203–210
  77. Goldstein MR. Lipid-altering drugs: decreasing cardiovascular disease at the expense of increasing cancer. Cancer Res. 2004;64:6831–6833
  78. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J. Pediatr. 2004;144:23–29
  79. Barker DJP. Mothers, Babies and Health in Later Life. London: Churchill Livingstone; 1998;p. 217
  80. Mellemkjaer L, Olsen ML, Sorensen HT, Thulstrup AM, Olsen J, Olsen JH. Birth weight and risk of early-onset breast cancer. Cancer Causes Control. 2003;14:61–64
  81. Berstein L. Newborn macrosomy and cancer. Adv. Cancer Res. 1988;50:231–278
  82. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause. 2003;10:332–336
  83. Herrington DM, Vittinhoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105:2962–2967
  84. Nuver J, Smit AJ, Potsma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat. Rep. 2002;28:195–214
  85. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 2004;140:786–794
  86. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070–2075
  87. Manhas A, Farmer JA. Hypolipidemic therapy and cholesterol absorption. Curr. Atheroscler. Rep. 2004;6:89–93
  88. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275–1281
  89. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. J. Am. Med. Assoc. 2004;291:2821–2827

PII: S0304-3835(04)00870-5

doi: 10.1016/j.canlet.2004.11.011

Cancer Letters
Volume 224, Issue 2 , Pages 203-212 , 28 June 2005

Article Tools